ArticleTropical medicine and infectious disease2026
Transmission Interruption of Leprosy in the Philippines: An Update on the Current Program Priorities and Interventions.
Article in Tropical medicine and infectious disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Philippines achieved World Health Organization (WHO) certification for the elimination of leprosy as a public health problem in 1998. Despite this milestone, new cases continue to be reported each year, highlighting the need for sustained surveillance and interventions to achieve zero transmission. This paper provides an update on the country's progress toward interruption of leprosy transmission using national surveillance data and programmatic reports from 2020-2024. Quantitative data were obtained from the Department of Health (DOH) Field Health Services Information System (FHSIS), while policy and programmatic information were drawn from national reports, WHO guidance, and implementation reviews. Descriptive analyses were conducted to examine trends in prevalence, case detection rates (CDRs), and age-sex distribution patterns to identify high-risk groups. Leprosy prevalence declined from 0.41 per 10,000 population in 2020 to 0.11 in 2024, remaining below the WHO elimination threshold. The CDR increased from 0.45 in 2022 to 1.17 per 100,000 in 2024, indicating recovery of active surveillance after COVID-19-related disruptions. Most newly detected cases occurred among adults aged 20-59 years (72%), although continued detection among children aged 0-14 years (6-7%) suggests ongoing transmission in selected endemic areas. Key program strengths include policy integration and WHO-supported surveillance initiatives, while major barriers include stigma, uneven local implementation, and limited access to rehabilitation. The Philippines has maintained low national prevalence while strengthening efforts toward transmission interruption. Continued investment in surveillance, contact tracing, stigma reduction, and integrated neglected tropical disease (NTD) services will be essential to achieving zero transmission, zero disability, and zero discrimination by 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.